Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.49
FLDM's Cash to Debt is ranked lower than
59% of the 2580 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 2.37 vs. FLDM: 0.49 )
FLDM' s 10-Year Cash to Debt Range
Min: 0.32   Max: No Debt
Current: 0.49

Equity to Asset 0.39
FLDM's Equity to Asset is ranked lower than
60% of the 2566 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 0.56 vs. FLDM: 0.39 )
FLDM' s 10-Year Equity to Asset Range
Min: -7.63   Max: 0.89
Current: 0.39

-7.63
0.89
F-Score: 1
Z-Score: 1.10
M-Score: -3.12
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -41.68
FLDM's Operating margin (%) is ranked lower than
71% of the 2589 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 3.94 vs. FLDM: -41.68 )
FLDM' s 10-Year Operating margin (%) Range
Min: -338.59   Max: -26.2
Current: -41.68

-338.59
-26.2
Net-margin (%) -40.03
FLDM's Net-margin (%) is ranked lower than
70% of the 2589 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 2.95 vs. FLDM: -40.03 )
FLDM' s 10-Year Net-margin (%) Range
Min: -368.13   Max: -23.22
Current: -40.03

-368.13
-23.22
ROE (%) -22.88
FLDM's ROE (%) is ranked lower than
67% of the 2563 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 5.65 vs. FLDM: -22.88 )
FLDM' s 10-Year ROE (%) Range
Min: -39.49   Max: -17.14
Current: -22.88

-39.49
-17.14
ROA (%) -8.86
FLDM's ROA (%) is ranked lower than
66% of the 2594 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 2.84 vs. FLDM: -8.86 )
FLDM' s 10-Year ROA (%) Range
Min: -91.18   Max: -14.14
Current: -8.86

-91.18
-14.14
ROC (Joel Greenblatt) (%) -227.42
FLDM's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 2585 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 10.67 vs. FLDM: -227.42 )
FLDM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -439.69   Max: -123.97
Current: -227.42

-439.69
-123.97
Revenue Growth (%) -46.00
FLDM's Revenue Growth (%) is ranked lower than
65% of the 1906 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 2.60 vs. FLDM: -46.00 )
FLDM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -36.3
Current: -46

EBITDA Growth (%) -57.70
FLDM's EBITDA Growth (%) is ranked lower than
63% of the 1552 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 2.40 vs. FLDM: -57.70 )
FLDM' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -54.9
Current: -57.7

EPS Growth (%) -58.30
FLDM's EPS Growth (%) is ranked lower than
62% of the 1376 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 2.30 vs. FLDM: -58.30 )
FLDM' s 10-Year EPS Growth (%) Range
Min: 0   Max: -53.4
Current: -58.3

» FLDM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

FLDM Guru Trades in Q3 2013

Jim Simons 135,900 sh (+749.38%)
PRIMECAP Management 3,768,321 sh (+0.59%)
Chuck Royce 3,300 sh (unchged)
» More
Q4 2013

FLDM Guru Trades in Q4 2013

Paul Tudor Jones 11,992 sh (New)
RS Investment Management 280,092 sh (New)
Chuck Royce Sold Out
PRIMECAP Management 3,484,821 sh (-7.52%)
Jim Simons 80,900 sh (-40.47%)
» More
Q1 2014

FLDM Guru Trades in Q1 2014

RS Investment Management 309,100 sh (+10.36%)
PRIMECAP Management 3,484,821 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2014

FLDM Guru Trades in Q2 2014

Jim Simons 49,500 sh (New)
RS Investment Management 524,648 sh (+69.73%)
PRIMECAP Management 3,651,332 sh (+4.78%)
» More
» Details

Insider Trades

Latest Guru Trades with FLDM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2013-06-30 Add 31.95%0.02%$16 - $19.04 $ 27.2155%3746323
PRIMECAP Management 2013-03-31 Add 113.65%0.04%$14.27 - $19.38 $ 27.2161%2839232
PRIMECAP Management 2012-12-31 Add 495.25%0.03%$13.63 - $17.02 $ 27.2184%1328900
PRIMECAP Management 2012-09-30 New Buy0.01%$12.8 - $17.15 $ 27.2184%223250
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.80
FLDM's P/B is ranked lower than
70% of the 2456 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 1.53 vs. FLDM: 4.80 )
FLDM' s 10-Year P/B Range
Min: 3.4   Max: 12.46
Current: 4.8

3.4
12.46
P/S 7.70
FLDM's P/S is ranked lower than
70% of the 2549 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 0.93 vs. FLDM: 7.70 )
FLDM' s 10-Year P/S Range
Min: 0.94   Max: 16.73
Current: 7.7

0.94
16.73
EV-to-EBIT -23.16
FLDM's EV-to-EBIT is ranked lower than
101% of the 1894 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 14.40 vs. FLDM: -23.16 )
FLDM' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -23.16

Current Ratio 4.67
FLDM's Current Ratio is ranked higher than
91% of the 2131 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 1.93 vs. FLDM: 4.67 )
FLDM' s 10-Year Current Ratio Range
Min: 1.13   Max: 8.73
Current: 4.67

1.13
8.73
Quick Ratio 4.07
FLDM's Quick Ratio is ranked higher than
93% of the 2131 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 1.43 vs. FLDM: 4.07 )
FLDM' s 10-Year Quick Ratio Range
Min: 0.86   Max: 8.11
Current: 4.07

0.86
8.11

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
FLDM's Price/Median PS Value is ranked higher than
51% of the 2475 Companies
in the Global Scientific & Technical Instruments industry.

( Industry Median: 1.14 vs. FLDM: 1.20 )
FLDM' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 2.04
Current: 1.2

0.14
2.04

Business Description

Industry: Computer Hardware » Scientific & Technical Instruments
Compare: » details
Traded in other countries:FLB.Germany
Fluidigm Corporation is a Delaware Corporation formed in 1999. The Company is a microfluidic systems for growth markets, such as single-cell genomics, applied genotyping, and sample preparation for targeted resequencing, in the life science and agricultural biotechnology, or Ag-Bio, industries. Its proprietary microfluidic systems consist of instruments and consumables, including integrated fluidic circuits, or IFCs, assays, and other reagents. These systems are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing the excellent data quality demanded by customers. The current markets for its products include life science research, clinical research, and Ag-Bio. The Company's primary area of focus within life science research is genetic analysis, the study of genes and their functions. Genetic analysis techniques, such as SNP genotyping, genotyping by sequencing, and genotyping by real-time PCR analysis, have become increasingly useful in Ag-Bio applications, including wildlife population studies, agricultural quality control, and commercial genetic engineering and identification. It actively market four microfluidic systems, including thirteen different commercial IFCs for nucleic acid analysis, as well as three families of assay chemistries. Its systems are based on one or more IFCs designed for particular applications and include specialized reagents, instrumentation, and software. The Company distributes its microfluidic systems through its direct sales force and support organizations located in North America, Europe, and Asia-Pacific, and through distributors or sales agents in several European, Latin American, Middle Eastern, and Asia-Pacific countries. It has have sold its C1 Single-Cell Auto Prep, BioMark, BioMark HD, EP1, and Access Array systems to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology and Ag-Bio companies. The Company has sold approximately 685 systems to customers in over 30 countries. Its microfluidic systems and instrumentation for commercial sale, as well as for internal research and development purposes, are manufactured at its facilities in Singapore. The Company also manufacture IFCs for research and development and its assay chemistries at its headquarters in South San Francisco, California. It competes with both established and development stage life science companies that design, manufacture, and market instruments for gene expression analysis, genotyping, other nucleic acid detection, and additional applications.
» More Articles for FLDM

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Sep 19 2014
Fluidigm’s New JunoTM System Shatters Barriers For SNP Genotyping Sep 16 2014
Fluidigm Corp. (FLDM) Worth Watching: Stock Up 5.1% Sep 03 2014
Fluidigm to Present at the Morgan Stanley Global Healthcare Conference Sep 02 2014
FLUIDIGM CORP Financials Aug 09 2014
UCSF/Fluidigm Paper Proves Shallow Sequencing of Related Single Cells Sufficient to Harvest... Aug 06 2014
FLUIDIGM CORP Files SEC form 10-Q, Quarterly Report Aug 04 2014
FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
Fluidigm Reports Q2 2014 Results Jul 31 2014
Fluidigm Announces Early Access Program for New Imaging Mass Cytometry Platform Jul 31 2014
Q2 2014 Fluidigm Corp Earnings Release - After Market Close Jul 31 2014
Fluidigm to Announce Q2 2014 Financial Results and Host Conference Call for Investors Jul 23 2014
Fluidigm expected to report strong quarter at Piper Jaffray Jul 10 2014
Single-Cell mRNA Sequencing Helps Reveal the Role of “Precocious” Dendritic Cells in... Jun 30 2014
FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Jun 10 2014
Fluidigm Ships FLEXsixTM Integrated Fluidic Circuits to Genotyping and Gene Expression Customers Jun 03 2014
FLUIDIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 28 2014
FLUIDIGM CORP Files SEC form 10-Q, Quarterly Report May 12 2014
Fluidigm to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference May 06 2014
Fluidigm's (FLDM) CEO Gajus Worthington on Q1 2014 Results - Earnings Call Transcript May 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK